Exact Goes All-In On Multi-Cancer Screening With $2.15Bn For Thrive; $410M For Base Genomics
Executive Summary
Deals give the company access to technologies to increase the accuracy of multi-cancer blood tests.
You may also be interested in...
In Vivo’s Deals Of The Year 2021: Cast Your Vote!
It is time for In Vivo's 14th annual Deals of the Year contest. We've selected 15 nominees across three categories – Top Alliance, Top Financing and Top M&A – and you get to pick the winners.
Investor Eye: Octopus Ventures Tackles Tough, Taboo Problems In Health Care
In an interview with Medtech Insight, Octopus Ventures partner Pooja Sikka explained the approach Octopus takes to investments, and the key challenges the fund wants to address.
Exact Sciences Acquires Ashion Analytics To Accelerate Sequencing Technology
The addition of the Arizona-based sequencing lab builds on Exact’s recent license of the TARDIS liquid biopsy technology from TGen.